调控性髓状细胞动力学 在喘患者在怀孕期间
medRxiv : the preprint server for health sciences
|June 26, 2025
概括
骨髓系衍生抑制细胞 (MDSCs) 在喘妇女中表现出明显的妊娠动态. 它们的水平与呼吸道炎症相关,但与健康怀孕不同的是,它们与母亲和胎儿的耐受性标志物无关.
科学领域:
- 免疫学 免疫学 免疫学
- 生殖免疫学 生殖免疫学
- 肺部病理学 肺部病理学
背景情况:
- 喘是孕妇常见的慢性炎症性肺病,恶化会影响结果.
- 骨髓衍生抑制细胞 (MDSCs) 是炎症和母胎耐受性的关键调节者.
研究的目的:
- 调查循环MDSC子集与呼吸道炎症指标和喘和没有喘的孕妇的母胎耐受性之间的相关性.
- 为了确定喘妊娠中母胎耐受性的潜在生物标志物.
主要方法:
- 招募健康孕妇 (HP),喘孕妇 (AP) 和控制良好的喘孕妇 (WCAP) 参与B-WELL母亲研究.
- 对循环中的髓衍生抑制细胞 (MDSC) 子集 (粒细胞和单细胞) 的分析.
- 与临床指标的相关性分析:部分呼出的氧化 (FeNO),可溶的HLA-G,以及胺2,3二氧化酶 (IDO) 活性.
主要成果:
- 粒细胞MDSCs (Gr-MDSCs) 在怀孕早期增加,并在怀孕晚期减少;单细胞MDSCs (Mo-MDSCs) 显示了相反的趋势.
- 与HP女性相比,AP/WCAP女性在怀孕晚期的Mo-MDSC下降率更高,Gr-MDSC下降率更低.
- 在AP/WCAP中,MDSC子集相互相关,Gr-MDSC与FeNO (气道炎症) 相相关.
- 可溶性HLA-G和IDO活性 (母胎耐受性标志物) 仅在HP女性中与MDSC相关,而不是在AP/WCAP女性中.
结论:
- 在喘妊娠中观察到MDSC子集的不同动态.
- 在患有喘的孕妇中,MDSC子集动态可以作为孕妇对母胎耐受性的潜在生物标志物.
- 怀孕期间的喘改变了MDSCs,呼吸道炎症和母胎耐受机制之间的关系.
相关概念视频
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
453
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
453
Asthma-I: Introduction
2.8K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K
Asthma-II: Pathophysiology and Classification
2.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K
Asthma: Pathogenesis and Management
613
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
613
Antiasthma Drugs: Leukotriene Modifiers
495
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
495
Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K


